Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a condition that causes blood vessel malformation met the main goal of safety and tolerability in a mid-stage study.

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like.

Is Recursion Pharmaceuticals a Warren Buffett Stock?

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma.

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Ginkgo Bioworks Holdings

AI holds tremendous promise for the biopharma industry. Using AI to identify candidates for new drugs is already happening.

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve the new-drug discovery process with artificial intelligence.

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder and Chief Executive Officer Najat Khan - Chief R&D and Commercial Officer Dave Hallett - Chief Executive Officer (Interim) and Chief Scientific Officer, Exscientia Conference Call Participants Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be joining you on our L(earnings) today.

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

ExScientia Ltd

On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX.

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read:

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.38 per share a year ago.

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) and Exscientia plc is fair to Recursion shareholders. Upon closing of the proposed transaction, Recursion shareholders will own approximately 74% of the combined company. Halper Sadeh encourages Recursion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0.

RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders

Operational complementarities expected to yield annual synergies of approximately $100 million Operational complementarities expected to yield annual synergies of approximately $100 million

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal, according to a statement seen by Reuters.

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets.  Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. This event is free, open to the public and encouraged, especially for those wishing to ask questions. Questions can be submitted at https://forms.gle/1LNMHJyWwUuH9sqJ8 . About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn. Forward-Looking Statements This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Report on Form 10-Q. All forward-looking statements are based on management's current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.Media Contact Media@Recursion.com

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Recursion could have three different revenue streams one day. Right now, it only has one but another may soon be within reach.

Is Recursion Pharmaceuticals a Millionaire-Maker?

Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

Recursion Pharmaceuticals uses AI in drug development, increasing success rates in lab and animal testing, with upcoming data readouts for five Phase 2 programs. The company is a "TechBio," with partnerships with big companies like Nvidia, focusing on AI-assisted drug discovery using Recursion OS. RXRX's lead molecule REC-994 shows promise in treating cerebral cavernous malformation, with potential billion-dollar opportunities and strong partnerships in the industry.

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Recursion Pharmaceuticals (RXRX) closed at $8.19 in the latest trading session, marking a -1.92% move from the prior day.

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

Recursion Pharmaceuticals is looking to revolutionize the drug development process. The biotech's strategy has yet to deliver major medical breakthroughs.

1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell

Medtronic

Novartis

While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing offered by AI can improve patient outcomes. From more precise diagnosis to pandemic modeling, the large-scale algorithmic models we call AI can help the world of medicine immensely.

3 Healthcare Stocks Injecting AI for Big Gains

Nano-X Imaging

NVIDIA

SoundHound AI Inc

Nano-X Imaging is especially popular with analysts. Recursion Pharmaceuticals plans to report results from seven clinical studies over the next 18 months.

These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street

Denali Therapeutics

Geron

The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs

Beam Therapeutics

Lilium BV

Amazon (NASDAQ: AMZN ) has more skin in the AI game than many people would like to think. Of course, the first thing that would spring to mind is the company's AWS cloud division.

News for Recursion Pharmaceuticals Stock (RXRX)